METHOD FOR RADIONUCLIDE DIAGNOSING OPERABLE BREAST CANCER WITH OVEREXPRESSION OF HER2/NEU Russian patent published in 2019 - IPC A61B6/03 A61K51/00 A61K103/10 A61P43/00 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology and radionuclide diagnostics, and can be used for diagnosing operable breast cancer with Her2/neu overexpression. Injection form of the radiopharmaceutical is introduced on the basis of technetium-99m labeled recombinant address molecules DARPin9_29, which is prepared immediately before administration. For this purpose in aseptic conditions 1 ml of eluate ^99mTcO^4- 7 GBq is added by syringe into kit for preparation of tricarbonyl technetium and incubated at temperature of 100 °C for 30 minutes. After incubation, 1,000 mcl of technetium tricarbonyl is added to 334 mcl of DARPin9_29 at concentration of basic substance solution of 3.6 mg/l and incubated at temperature of 40 °C for 60 minutes. Further, the obtained compound is purified from protein impurities and non-technetium-bound DARPin9_29 molecules by means of cleaning columns. 500-MBq-produced preparation is diluted in 10 ml of physiologic saline and slowly introduced into the patient through a sterilizing filter. In 4 hours after administration of the preparation, a single-photon emission computed tomography is performed on a two-detector gamma camera. Obtained results are evaluated and the malignant tumor is diagnosed when visualizing the RFP fixation in the mammary gland tissues.

EFFECT: technical result provides higher specificity, information value and accessibility of diagnosing operable breast cancer with Her2/neu overexpression.

1 cl, 2 dwg, 2 ex